Declining incidence of keratinocyte carcinoma in organ transplant recipients.
Adolescent
Adult
Aged
Carcinoma, Basal Cell
/ epidemiology
Carcinoma, Squamous Cell
/ epidemiology
Child
Child, Preschool
Female
Follow-Up Studies
Graft Rejection
/ immunology
Humans
Immunosuppression Therapy
/ adverse effects
Incidence
Infant
Ireland
/ epidemiology
Male
Middle Aged
Organ Transplantation
/ adverse effects
Registries
/ statistics & numerical data
Skin Neoplasms
/ epidemiology
Transplant Recipients
/ statistics & numerical data
Young Adult
Journal
The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
accepted:
30
04
2019
pubmed:
3
5
2019
medline:
12
1
2021
entrez:
4
5
2019
Statut:
ppublish
Résumé
All organ transplant populations are predisposed to increased rates of keratinocyte carcinoma (KC). Since this increased risk was first appreciated, immunosuppressive regimens have changed and organ transplant recipients (OTRs) have been aggressively screened for KC. There is a perception that these measures have impacted on KC incidence but there is a paucity of population-based studies on post-transplant rates of basal cell carcinoma (BCC). To identify trends in incidence rates for KC following solid organ transplantation over the past two decades. This nationwide, population-based study included all solid OTRs transplanted between 1994 and 2014. Patient data were matched to national cancer registry data to determine the standardized incidence ratio (SIR) of KC in solid OTRs compared with the general population. In total 3580 solid OTRs were included. The total follow-up time was 28 407 person-years (median follow-up 7·11 years). The overall SIRs for squamous cell carcinoma (SCC) and BCC were 19·7 and 7·0, respectively. Our study documents a progressive fall in the SIRs for SCC and BCC from peak SIRs (95% confidence intervals) in 1994-1996 of 26·4 (21·5-32·4) and 9·1 (7·4-11·3) to 6·3 (2·3-16·7) and 3·2 (1·4-7·1) in 2012-2014, respectively. The ratio of SCC to BCC has remained at 3 to 1 over the last two decades. Our study is the first to demonstrate a significant reduction over the past two decades in the incidences of both SCC and BCC following solid organ transplantation. The SCC-to-BCC ratio was maintained, demonstrating that both are reducing equally. This trend coincided with temporal changes in immunosuppressive protocols and the introduction of skin cancer prevention programmes. What's already known about this topic? Prior studies have shown that the risk of cutaneous squamous cell carcinoma (SCC) has declined over recent decades following solid organ transplantation. It is not known whether the risk of basal cell carcinoma (BCC) has reduced in line with this. What does this study add? Our study documents a progressive fall in the risk of SCC and BCC following solid organ transplantation over the last two decades. The SCC-to-BCC ratio was maintained, demonstrating that both are reducing equally. The trends observed in our study coincided with temporal changes in immunosuppressive protocols and the introduction of cancer prevention programmes, suggesting that these factors have positively impacted on the risk of keratinocyte carcinoma in this cohort.
Sections du résumé
BACKGROUND
All organ transplant populations are predisposed to increased rates of keratinocyte carcinoma (KC). Since this increased risk was first appreciated, immunosuppressive regimens have changed and organ transplant recipients (OTRs) have been aggressively screened for KC. There is a perception that these measures have impacted on KC incidence but there is a paucity of population-based studies on post-transplant rates of basal cell carcinoma (BCC).
OBJECTIVES
To identify trends in incidence rates for KC following solid organ transplantation over the past two decades.
METHODS
This nationwide, population-based study included all solid OTRs transplanted between 1994 and 2014. Patient data were matched to national cancer registry data to determine the standardized incidence ratio (SIR) of KC in solid OTRs compared with the general population.
RESULTS
In total 3580 solid OTRs were included. The total follow-up time was 28 407 person-years (median follow-up 7·11 years). The overall SIRs for squamous cell carcinoma (SCC) and BCC were 19·7 and 7·0, respectively. Our study documents a progressive fall in the SIRs for SCC and BCC from peak SIRs (95% confidence intervals) in 1994-1996 of 26·4 (21·5-32·4) and 9·1 (7·4-11·3) to 6·3 (2·3-16·7) and 3·2 (1·4-7·1) in 2012-2014, respectively. The ratio of SCC to BCC has remained at 3 to 1 over the last two decades.
CONCLUSIONS
Our study is the first to demonstrate a significant reduction over the past two decades in the incidences of both SCC and BCC following solid organ transplantation. The SCC-to-BCC ratio was maintained, demonstrating that both are reducing equally. This trend coincided with temporal changes in immunosuppressive protocols and the introduction of skin cancer prevention programmes. What's already known about this topic? Prior studies have shown that the risk of cutaneous squamous cell carcinoma (SCC) has declined over recent decades following solid organ transplantation. It is not known whether the risk of basal cell carcinoma (BCC) has reduced in line with this. What does this study add? Our study documents a progressive fall in the risk of SCC and BCC following solid organ transplantation over the last two decades. The SCC-to-BCC ratio was maintained, demonstrating that both are reducing equally. The trends observed in our study coincided with temporal changes in immunosuppressive protocols and the introduction of cancer prevention programmes, suggesting that these factors have positively impacted on the risk of keratinocyte carcinoma in this cohort.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
983-991Subventions
Organisme : The City of Dublin Skin and Cancer Hospital Charity
Pays : International
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 British Association of Dermatologists.
Références
Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348:1681-91.
National Cancer Registry Ireland. Cancer trends. Available at: https://www.ncri.ie/sites/ncri/files/pubs/Trends%20report%20skin%20cancer%20final180717.pdf (last accessed 24 June 2019).
Harwood CA, Mesher D, McGregor JM et al. A surveillance model for skin cancer in organ transplant recipients: a 22-year prospective study in an ethnically diverse population. Am J Transplant 2013; 13:119-29.
Hertz MI, Aurora P, Benden C et al. Scientific registry of the International Society for Heart and Lung Transplantation: introduction to the 2011 annual reports. J Heart Lung Transplant 2011; 30:1071-7.
U.S. Department of Health and Human Services. Organ Procurement and Transplant Network. Available at: http://optn.transplant.hrsa.gov (last accessed 24 June 2019).
Rana A, Gruessner A, Agopian VG et al. Survival benefit of solid-organ transplant izn the United States. JAMA Surg 2015; 150:252-9.
Rizvi SMH, Aagnes B, Holdaas H et al. Long term change in the risk of skin cancer after organ transplantation. A population-based nationwide cohort study. JAMA Dermatol 2017; 153:1270-7.
Wisgerhof HC, Wolterbeek R, de Fijter JW et al. Kidney transplant recipients with cutaneous squamous cell carcinoma have an increased risk of internal malignancy. J Invest Dermatol 2012; 132:2176-83.
Krynitz B, Edgren G, Lindelöf B et al. Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008 - a Swedish population-based study. Int J Cancer 2013; 132:1429-38.
Moloney FJ, de Freitas D, Conlon P, Murphy GM. Renal transplantation, immunosuppression and the skin: an update. Photodermatol Photoimmunol Photomed 2005; 21:1-8.
Moloney FJ, Comber H, O'Lorcain P et al. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 2006; 154:498-504.
Bordea C, Wojnarowska F, Millard PR et al. Skin cancers in renal-transplant recipients occur more frequently than previously recognized in a temperate climate. Transplantation 2004; 77:574-9.
Mackenzie KA, Wells JE, Lynn KL et al. First and subsequent nonmelanoma skin cancers: incidence and predictors in a population of New Zealand renal transplant recipients. Nephrol Dial Transplant 2010; 25:300-6.
Damian DL, Patterson CR, Stapelberg M et al. UV radiation-induced immunosuppression is greater in men and prevented by topical nicotinamide. J Invest Dermatol 2008; 128:447-54.
Naldi L, Fortina AB, Lovati S et al. Risk of nonmelanoma skin cancer in Italian organ transplant recipients. A registry-based study. Transplantation 2000; 70:1479-84.
Fuente MJ, Sabat M, Roca J et al. A prospective study of the incidence of skin cancer and its risk factors in a Spanish Mediterranean population of kidney transplant recipients. Br J Dermatol 2003; 149:1221-6.
Euvrard S, Kanitakis J, Pouteil-Noble C et al. Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. J Am Acad Dermatol 1995; 33:222-9.
Webb MC, Compton F, Andrews PA, Koffman CG. Skin tumours posttransplantation: a retrospective analysis of 28 years’ experience at a single centre. Transplant Proc 1997; 29:828-30.
Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357:2562-75.
Salgo R, Gossmann J, Schofer H et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 2010; 10:1385-93.
Kauffman HM, Cherikh WS, McBride MA et al. Post-transplant de novo malignancies in renal transplant recipients: the past and present. Transplant Int 2006; 19:607-20.
Coghill AE, Johnson LG, Berg D et al. Immunosuppressive medications and squamous cell skin carcinoma: nested case-control study within the Skin Cancer after Organ Transplant (SCOT) cohort. Am J Transplant 2016; 16:565-73.
Green A, Williams G, Neale R et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 1999; 354:723-9.
Ismail F, Mitchell L, Casabonne D et al. Specialist dermatology clinics for organ transplant recipients significantly improve compliance with photoprotection and levels of skin cancer awareness. Br J Dermatol 2006; 155:916-25.
Bavinck JN, Tieben LM, Van der Woude FJ et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 1995; 13:1933-8.
Chen K, Craig JC, Shumack S. Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials. Br J Dermatol 2005; 152:518-23.
Chen AC, Martin AJ, Choy B et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med 2015; 373:1618-26.